Grace Therapeutics, Inc.
GRCE
$2.99
-$0.05-1.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.91% | 25.56% | 65.52% | 71.18% | 72.70% |
| Total Depreciation and Amortization | 60.00% | -36.36% | -66.67% | -81.48% | 113.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,945.28% | -417.83% | -106.66% | -109.36% | -99.59% |
| Change in Net Operating Assets | -87.13% | 126.80% | 168.24% | 206.54% | 386.93% |
| Cash from Operations | -35.30% | -20.85% | -3.44% | 23.28% | 42.08% |
| Capital Expenditure | -- | -- | -175.00% | -175.00% | -120.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -99.09% | -99.09% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | 522.72% | 100.00% | 100.00% |
| Cash from Investing | -83.15% | -100.00% | 550.96% | -120.79% | 184.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 99.43% | 99.43% | -97.80% | -97.80% | 6,800.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -698.77% | -496.91% | -- | -- | -- |
| Cash from Financing | 86.23% | 90.68% | -100.00% | -100.00% | 6,651.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | 109.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 127.29% | 82.09% | 2.68% | -49.16% | 86.63% |